PPARG and thyroid cancer: The upregulation of endogenous PPARγ ligands such as PGJ2 and 15(S)-HETE appears to be a better strategy than the administration of a synthetic PPARγ ligand to inhibit thyroid cancer, at least in terms of side-effects.